Clinical Evidence & Information

Periprocedural Multiplate testing commonly led clinicians to prescribe low-dose antiplatelet therapy in patients undergoing elective flow diversion for internal carotid artery aneurysms, with a low overall rate of major stroke or neurological death.

For the first time, ICU clinicians have a bedside number that tells them not just how sick their septic patient is, but whether their fibrinolysis is recoverable — and whether today's treatment is working.

A whole-blood, tPA-challenged fibrinolysis readout that helps identify when antifibrinolytic effect is present and when fibrinolytic susceptibility remains high.

Fibrinogen and FXIII should be considered together as a clot-stability unit

Many patients on standard dual antiplatelet therapy exhibit high on-treatment platelet reactivity (HTPR) , a risk factor for post-procedural thrombotic events.

Rapid urine DOAC screening may support thrombolysis and reversal decisions when plasma assays are slow or unavailable

ClotPro CT IN/HI ratio showed better agreement with Anti-Xa than aPTT and provides a whole-blood point-of-care UFH signal.

This proof-of-concept study addresses a practical gap in cardiac surgery

Viscoelastometry may help guide thrombolysis decisions and bleeding-risk assessment in acute PE.

This case demonstrates that seizures can be triggered immediately after high-dose TXA administration

Anti-Xa has never been validated as a UFH reference standard in CPB or ECMO, so all monitoring tools need context-specific validation.

Triple-bolus TXA reduced early postoperative bleeding versus bolus-plus-infusion without a seizure or thromboembolic signal in this cohort

TXA can be pro- or antifibrinolytic depending on plasminogen levels and timing; therapeutic co-administration with tPA produced consistent antifibrinolytic effects.

Low ML should not always be assumed to represent hyperfibrinolysis or normal fibrinolysis.